Biocartis Group NV (LTS:0R72) Days Payable: 127.20 (As of Jun. 2023)

What is Biocartis Group NV Days Payable?

Biocartis Group NV LTS:0R72 14 Days Payable is 127.20 as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Biocartis Group NV's average Accounts Payable for the six months ended in Jun. 2023 was €9.32 Mil. Biocartis Group NV's Cost of Goods Sold for the six months ended in Jun. 2023 was €13.38 Mil. Hence, Biocartis Group NV's Days Payable for the six months ended in Jun. 2023 was 127.20.

The historical rank and industry rank for Biocartis Group NV's Days Payable or its related term are showing as below:

LTS:0R72's Days Payable is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 65.385
* Ranked among companies with meaningful Days Payable only.

Biocartis Group NV's Days Payable declined from Jun. 2022 (141.95) to Jun. 2023 (127.20). It may suggest that Biocartis Group NV accelerated paying its suppliers.

Biocartis Group NV Days Payable Related Terms

Biocartis Group NV Days Payable Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV Days Payable Chart

Biocartis Group NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

160.85

145.83

159.54

137.01

142.74

Biocartis Group NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial															137.84	126.76	141.95	122.18	127.20

LTS:0R72 vs TMO, DHR, IDXX: Days Payable Comparison

For the Diagnostics & Research subindustry, Biocartis Group NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocartis Group NV Days Payable vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Days Payable distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's Days Payable falls into.

Save Embed

14GF Score

Biocartis Group NV LTS:0R72

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biocartis Group NV Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Biocartis Group NV's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (11.56	+	11.747)	/	2 )	/	29.799	*	365
=	11.6535					/	29.799	*	365
=	142.74

Biocartis Group NV's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (11.747	+	6.902)	/	2 )	/	13.378	*	365 / 2
=	9.3245					/	13.378	*	365 / 2
=	127.20

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 127.20 mean?

Biocartis Group NV (LTS:0R72) has a Days Payable of 127.20 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocartis Group NV and its competitors.

Is Biocartis Group NV's Days Payable too high?

Biocartis Group NV's current Days Payable is 127.20. The Medical Diagnostics & Research industry median Days Payable is 65.39. Biocartis Group NV's value of 127.20 is 94.5% above this industry median. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Biocartis Group NV's Days Payable compare to TMO and DHR?

Biocartis Group NV's Days Payable of 127.20 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Days Payable is 65.39. Biocartis Group NV's value of 127.20 is 94.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Medical Diagnostics & Research company?

The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocartis Group NV's current Days Payable of 127.20 is 94.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocartis Group NV and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocartis Group NV's current Days Payable is 127.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biocartis Group NV stock overvalued right now?

Biocartis Group NV (LTS:0R72) has a current Days Payable of 127.20. The current Days Payable is 127.20 and 94.5% above the Medical Diagnostics & Research industry median of 65.39. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Days Payable is 127.20 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies XBRU:MDXH TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX WAT XPAR:BIM EXAS RVTY XPAR:ERF ASX:SHL CRL

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800

Website https://www.biocartis.com

Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.

14GF Score

Get the complete analysis for LTS:0R72

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30

Price

View LTS:0R72 Analysis

See Days Payable data for all stocks →